Month: September 2021

– Rapid and sustained improvement in urticaria control after single dose of CDX-0159 –– Greatly improved patient quality of life and reduced disease impact –– Data further support 95% complete response rate to provocation testing – HAMPTON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive data on measurements of symptom control and quality of life from the Company’s ongoing, open label Phase 1b clinical trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria. These diseases, which are often severe and debilitating, can significantly impact patients’ lives. CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor...

HighlightsUpdated Measured and Indicated resource for the Maricunga Stage One Lithium Brine Project in Chile confirmed an increase by 90 per cent compared with 2019 Definitive Feasibility Study. Measured and Indicated (M&I) resource now estimated as 1,905,000 tonnes of Lithium Carbonate Equivalent (LCE) for the Stage One (Old Code) mining properties at an average grade of 953 mg/l lithium. This increase in M+I Resources is in addition to the M+I Resources (2018) of 184 Kt Lithium (979 Kt LCE) in the Litio 1-6 (New Code) concessions to a depth of 200 m. The Maricunga resource remains open at depth, with a new exploration target for further resource expansion between 400m-550m in the Stage One concessions. The DFS update for the Stage One continues as expected by Worley, GEA Messo and Atacama Waters. The latest drilling for the resource...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 28, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) announces that new and updated clinical data from several ongoing combination studies of surufatinib (SULANDA® in China) or fruquintinib (ELUNATE® in China) with PD-1 inhibitors were presented at the 24th Chinese Society of Clinical Oncology (CSCO) Annual Meeting which has been taking place on September 25-29, 2021. SURUFATINIBTitle: A phase II study of surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: an updated analysisLead Author Lin Shen, MD, Peking University Cancer Hospital & InstituteType: Oral presentationSession Number: CSCO Innovation Presentation 1-Session 2-#13   Patients with advanced neuroendocrine...

HONG KONG and FLORHAM PARK, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, further to its announcement in March 2021 and following receipt of regulatory approval, it has completed the sale of its entire indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), a non-core and non-consolidated over-the-counter (“OTC”) drug joint venture business, to GL Mountrose Investment Two Limited, a company controlled and managed by GL Capital Group (“GL Capital”). The aggregate amount which will be received by HUTCHMED is approximately US$169 million in cash, representing about 22 times HBYS’ adjusted net profit attributable to HUTCHMED equity holders of US$7.7 million in 20201. Of the proceeds, approximately US$127 million...

VANCOUVER, British Columbia, Sept. 28, 2021 (GLOBE NEWSWIRE) — Nanotech Security Corp. (TSXV: NTS) (OTCQX: NTSFF) (“Nanotech” or the “Company”), a leader in the development of secure and visually memorable nano-optic security features used in the government and banknote and brand protection markets, is pleased to announce that, at its special meeting (the “Meeting”) of securityholders of Nanotech (the “Nanotech Securityholders”), Nanotech Securityholders approved the plan of arrangement (the “Arrangement”) with Meta Materials Inc. (“META”), pursuant to which, among other things, META will indirectly acquire all of the issued and outstanding common shares in the authorized share structure of Nanotech (the “Common Shares”) for $1.25 in cash in exchange for each Common Share held, which was previously announced on August 5, 2021. The...

False Advertising Lawsuit Against Natera is Set to Go to Trial CareDx Plans to Appeal Recent Ruling in Patent Case SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that in a hearing today, the District Court confirmed that the false advertising case against Natera will proceed to trial. The current trial date is October 25, 2021. CareDx also issued the following statement regarding its patent infringement case against Natera, which is unrelated to the false advertising case. “CareDx respectfully disagrees with the court’s ruling and intends to appeal. While the trial court’s...